Sonoma Pharmaceuticals (SNOA)
Market Price (2/16/2026): $2.77 | Market Cap: $4.7 MilSector: Health Care | Industry: Pharmaceuticals
Sonoma Pharmaceuticals (SNOA)
Market Price (2/16/2026): $2.77Market Cap: $4.7 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -40% | Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -157% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -16% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -21% | |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -76% | |
| High stock price volatilityVol 12M is 131% | ||
| Key risksSNOA key risks include [1] its current unprofitability and challenging need for additional capital given its small market cap and past shareholder dilution, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -40% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -30% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management. |
| Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -157% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -16% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -21% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -76% |
| High stock price volatilityVol 12M is 131% |
| Key risksSNOA key risks include [1] its current unprofitability and challenging need for additional capital given its small market cap and past shareholder dilution, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Sonoma Pharmaceuticals (SNOA) stock has lost about 30% since 10/31/2025 because of the following key factors:
1. Continuing Net Losses and Negative Analyst Outlook: Despite reporting revenue increases, Sonoma Pharmaceuticals has consistently faced net losses. For example, while Q3 2026 showed a decrease in net loss compared to the prior year, the company still reported a net loss. Analysts anticipate further decreases in earnings per share (EPS) for the upcoming year, projecting a decline from ($0.67) to ($1.79) per share. This sustained unprofitability and bleak future earnings expectations likely contribute to investor apprehension and stock devaluation.
2. Bearish Market Sentiment and Technical Signals: The stock has been under significant selling pressure, with technical analysis on February 9, 2026, indicating a "Strong Sell" signal and a persistent falling trend. This strong bearish sentiment suggests that market momentum is firmly against the stock, contributing to its decline.
Show more
1. Continuing Net Losses and Negative Analyst Outlook: Despite reporting revenue increases, Sonoma Pharmaceuticals has consistently faced net losses. For example, while Q3 2026 showed a decrease in net loss compared to the prior year, the company still reported a net loss. Analysts anticipate further decreases in earnings per share (EPS) for the upcoming year, projecting a decline from ($0.67) to ($1.79) per share. This sustained unprofitability and bleak future earnings expectations likely contribute to investor apprehension and stock devaluation.
2. Bearish Market Sentiment and Technical Signals: The stock has been under significant selling pressure, with technical analysis on February 9, 2026, indicating a "Strong Sell" signal and a persistent falling trend. This strong bearish sentiment suggests that market momentum is firmly against the stock, contributing to its decline.
Show more
Stock Movement Drivers
Fundamental Drivers
The -30.2% change in SNOA stock from 10/31/2025 to 2/15/2026 was primarily driven by a -38.7% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.94 | 2.75 | -30.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 15 | 18 | 18.8% |
| P/S Multiple | 0.4 | 0.3 | -38.7% |
| Shares Outstanding (Mil) | 2 | 2 | -4.2% |
| Cumulative Contribution | -30.2% |
Market Drivers
10/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| SNOA | -30.2% | |
| Market (SPY) | -0.0% | 14.2% |
| Sector (XLV) | 9.3% | 3.4% |
Fundamental Drivers
The -7.7% change in SNOA stock from 7/31/2025 to 2/15/2026 was primarily driven by a -21.0% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.98 | 2.75 | -7.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 18 | 24.0% |
| P/S Multiple | 0.3 | 0.3 | -21.0% |
| Shares Outstanding (Mil) | 2 | 2 | -5.8% |
| Cumulative Contribution | -7.7% |
Market Drivers
7/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| SNOA | -7.7% | |
| Market (SPY) | 8.2% | 8.3% |
| Sector (XLV) | 21.4% | 4.1% |
Fundamental Drivers
The 2.2% change in SNOA stock from 1/31/2025 to 2/15/2026 was primarily driven by a 30.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.69 | 2.75 | 2.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 18 | 30.8% |
| P/S Multiple | 0.2 | 0.3 | 29.5% |
| Shares Outstanding (Mil) | 1 | 2 | -39.6% |
| Cumulative Contribution | 2.2% |
Market Drivers
1/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| SNOA | 2.2% | |
| Market (SPY) | 14.3% | 17.6% |
| Sector (XLV) | 8.8% | 12.2% |
Fundamental Drivers
The -91.7% change in SNOA stock from 1/31/2023 to 2/15/2026 was primarily driven by a -90.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.20 | 2.75 | -91.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13 | 18 | 41.6% |
| P/S Multiple | 0.4 | 0.3 | -35.4% |
| Shares Outstanding (Mil) | 0 | 2 | -90.9% |
| Cumulative Contribution | -91.7% |
Market Drivers
1/31/2023 to 2/15/2026| Return | Correlation | |
|---|---|---|
| SNOA | -91.7% | |
| Market (SPY) | 74.0% | 12.2% |
| Sector (XLV) | 23.7% | 10.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SNOA Return | -37% | -75% | -84% | -25% | 35% | -24% | -98% |
| Peers Return | 4% | -27% | 44% | 29% | 9% | -10% | 39% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| SNOA Win Rate | 25% | 25% | 50% | 50% | 42% | 0% | |
| Peers Win Rate | 53% | 37% | 57% | 45% | 40% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| SNOA Max Drawdown | -40% | -78% | -87% | -30% | -30% | -24% | |
| Peers Max Drawdown | -12% | -54% | -25% | -34% | -41% | -15% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IART, MDXG, BHC, HROW, ELAN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | SNOA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.5% | -25.4% |
| % Gain to Breakeven | 6756.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -37.4% | -33.9% |
| % Gain to Breakeven | 59.9% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -94.5% | -19.8% |
| % Gain to Breakeven | 1708.8% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to IART, MDXG, BHC, HROW, ELAN
In The Past
Sonoma Pharmaceuticals's stock fell -98.5% during the 2022 Inflation Shock from a high on 2/16/2021. A -98.5% loss requires a 6756.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Sonoma Pharmaceuticals (SNOA)
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Sonoma Pharmaceuticals (SNOA):
- A specialized pharmaceutical company focusing on skin and wound care, similar to a focused version of Johnson & Johnson's medical or consumer health divisions.
- A pharmaceutical company offering topical treatments and medical solutions, akin to a smaller, more specialized Bayer focused on dermatology and wound care.
AI Analysis | Feedback
- Dermatology Products: Sonoma Pharmaceuticals offers a range of prescription and over-the-counter topical solutions and gels for various skin conditions like acne, eczema, and rosacea.
- Wound Care Products: These include prescription solutions and gels primarily for the treatment and management of acute and chronic wounds, including diabetic foot ulcers and burns.
- Animal Health Products: The company provides topical solutions and gels specifically designed for wound care and skin conditions in animals.
AI Analysis | Feedback
Sonoma Pharmaceuticals (SNOA)
Sonoma Pharmaceuticals primarily sells its products to other companies, which then distribute or sell the products to healthcare providers and, in some cases, directly to individuals. The company's major customers, as disclosed in its financial filings, are:- Cardinal Health (CAH)
- McKesson Medical-Surgical (a subsidiary of McKesson Corporation - MCK)
AI Analysis | Feedback
- MicroSafe Group
- Smith & Nephew (SNN)
- Te Arai BioFarma
AI Analysis | Feedback
Amy Trombly, Chief Executive Officer
Amy Trombly has two decades of experience counseling public companies in corporate and securities law, as well as mergers and acquisitions. She has owned and managed Trombly Business Law, PC since 2002. Earlier in her career, Ms. Trombly served as a Vice President at State Street Bank and as Special Counsel at the U.S. Securities and Exchange Commission.
Jerry Dvonch, Chief Financial Officer
Jerry Dvonch joined Sonoma Pharmaceuticals from SpineCenter Atlanta, where he was the controller and Senior Vice President of Finance and Accounting since March 2017. Previously, he was a consultant controller for DS Healthcare Group, Inc. from March 2016 to April 2016. From July 2005 to July 2015, he held positions as the director for external reporting and director of finance at NeoGenomics Laboratories. Mr. Dvonch is a licensed Certified Public Accountant in New York and possesses over 10 years of experience with SEC reporting.
Bruce Thornton, Chief Operating Officer
Bruce Thornton has served as Sonoma Pharmaceuticals' Chief Operating Officer, Vice President of Global Operations, and US General Manager since 2004. Prior to this, he was the Vice President of Operations for Jomed (formerly EndoSonic Corp.) from January 1999 to September 2003, and then Vice President of Manufacturing for Volcano Therapeutics following its acquisition of Jomed, until March 2004.
Jerry McLaughlin, Lead Independent Director
Jerry McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. Since April 2011, he has been the founder, Chairman, and Chief Executive Officer of DataStream Medical Imaging Systems, Inc. His past roles include President of DataFlow Information Systems from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007.
Philippe Weigerstorfer, Independent Director
Philippe Weigerstorfer contributes extensive pharmaceutical and dermatology experience to Sonoma's board and has a history of expanding businesses internationally. He started his career in marketing at Sandoz and Novartis, moving into leadership roles for global business units in cardiovascular, dermatology, and other areas. In 1999, he joined Galencia Ltd's executive team, where he managed retail, pre-wholesale, business development, and M&A divisions.
AI Analysis | Feedback
Key Risks to Sonoma Pharmaceuticals (SNOA)
Sonoma Pharmaceuticals (SNOA) faces several significant risks to its business operations and financial stability. These can be broadly categorized as follows:
- Financial Viability and Capital Needs: Sonoma Pharmaceuticals is currently unprofitable and its ability to generate sufficient revenue to cover its cash needs and fund ongoing development is a primary concern. The company's small market capitalization and past shareholder dilution further highlight the challenges related to its financial and corporate stability. The volatility of its stock price is also influenced by its ability to secure additional capital.
- Regulatory and Clinical Development Risks: The company's business is highly dependent on regulatory and clinical developments. Risks include potential changes in regulatory guidelines, the possibility that scientific data may not meet regulatory standards, and the need to obtain required regulatory clearances or approvals for its products. There is also a risk that positive clinical results observed in trials may not be successfully replicated in real-world patient settings.
- Market Competition and Product Penetration: Sonoma Pharmaceuticals operates in a competitive pharmaceutical industry. Key risks include the potential that the target market for its products may not be as large as anticipated, and challenges in effectively penetrating targeted markets. The success of its distribution partners in marketing and selling products also plays a crucial role and presents an operational risk.
AI Analysis | Feedback
null
AI Analysis | Feedback
Sonoma Pharmaceuticals (SNOA) develops and produces stabilized hypochlorous acid (HOCl) products using its patented Microcyn® Technology for a variety of applications, including wound care, dermatology, eye care, oral and nasal care, podiatry, animal health care, and non-toxic disinfectants. The addressable markets for their main products and services are as follows:
- U.S. Skin Care Market: This market, which includes dermatology and cosmetics, is projected to reach nearly $40 billion by 2030.
- Global Eye Care Market: The global eye care market size was estimated at $70.78 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.72% from 2024 to 2030.
- U.S. Advanced Wound Care OTC Market: This market was estimated at $2.77 billion in 2024 and is projected to reach $6.61 billion by 2033, with a CAGR of 10.33% from 2025 to 2033.
- Global Wound Irrigation Systems Market: This market was valued at approximately $318.7 million in 2024 and is predicted to grow to around $496.4 million by 2035, with a CAGR of 4.11% from 2025 to 2035.
- Global Natural Skin Care Products Market: This market was valued at $6.7 billion in 2021 and is expected to expand at a CAGR of 6.6% from 2022 to 2030.
- Global Animal Health Market: The global animal health market size was valued at $62.40 billion in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030.
AI Analysis | Feedback
Sonoma Pharmaceuticals (SNOA) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Launch of New Products: The company continues to invest in research and development, leading to the introduction of new products. Recent examples include Lumacyn™ Clarifying Mist for skincare (January 2024), expanded sizes for Microcyn® Negative Pressure Wound Therapy Solution products (April 2024), hypochlorous acid-based acne products launched in over 1,200 UK stores (April 2025), HOCl-based diaper rash products with Walmart (August 2025), and a new HOCl wound cleanser with Medline Industries (October 2025). These new offerings are anticipated to contribute significantly to revenue growth.
- Expansion of Distribution Networks and Partnerships: Sonoma Pharmaceuticals is actively growing its distribution network and forging new partnerships. This includes expanding its MicrocynAH® animal health care products into additional retail chains like Menards® (May 2024), forming an agreement with NovaBay Pharmaceuticals for the sale and marketing of Avenova®-branded products in the European Union (January 2024), and broadening partnerships with major U.S. retailers for consumer-focused products (July 2025). The company has also added a new distributor in Ukraine.
- International Market Expansion and Regulatory Approvals: Sonoma is focused on expanding its global footprint by aggressively pursuing worldwide regulatory approvals. Notable achievements include the successful transition of all commercialized European products to the new EU Medical Device Regulation (MDR) ahead of the 2028 deadline and registration of products with the MHRA in the United Kingdom (June 2025). Additionally, they received regulatory approval for wound care products in Ukraine (April 2025), contributing to increased European and Latin American sales.
- Growth in Key Product Categories, particularly Dermatology and Wound Care: The company sees strong potential in specific therapeutic areas. U.S. sales have shown growth driven by consumer-focused animal health care and wound care products. Dermatology is highlighted as a high-margin area for growth, with efforts to position products for med spas and dermatologists, including office dispense lines. Wound care remains a stable and growing segment.
- Increasing Demand for Microcyn® Technology: Underlying all these efforts is the sustained and growing worldwide demand for Sonoma's patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products across various applications. The CEO has explicitly stated "significant worldwide demand for our technology" as a driver.
AI Analysis | Feedback
Share Issuance
- Sonoma Pharmaceuticals implemented a 1-for-20 reverse stock split effective August 29, 2024, reducing the number of outstanding common shares from approximately 20 million to about 1 million.
- Concurrently with the reverse stock split, the company increased its authorized shares of common stock from 24,000,000 to 50,000,000.
- The number of issued and outstanding shares increased from 1,634,265 on March 31, 2025, to 1,649,765 on September 30, 2025, and reached 1,701,076 as of November 3, 2025.
Capital Expenditures
- Capital expenditures were reported at $106,000 in the first quarter of fiscal 2025.
- These capital expenditures are considered calculated spending intended to facilitate growth.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Sonoma Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.66 |
| Mkt Cap | 1.3 |
| Rev LTM | 1,018 |
| Op Inc LTM | 42 |
| FCF LTM | 30 |
| FCF 3Y Avg | 43 |
| CFO LTM | 79 |
| CFO 3Y Avg | 88 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.3% |
| Rev Chg 3Y Avg | 10.0% |
| Rev Chg Q | 16.2% |
| QoQ Delta Rev Chg LTM | 3.5% |
| Op Mgn LTM | 8.2% |
| Op Mgn 3Y Avg | 5.3% |
| QoQ Delta Op Mgn LTM | 1.5% |
| CFO/Rev LTM | 10.4% |
| CFO/Rev 3Y Avg | 8.9% |
| FCF/Rev LTM | 3.4% |
| FCF/Rev 3Y Avg | 3.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.3 |
| P/S | 1.2 |
| P/EBIT | 7.5 |
| P/E | 2.4 |
| P/CFO | 10.5 |
| Total Yield | 0.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.1% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -7.2% |
| 3M Rtn | -4.1% |
| 6M Rtn | -24.1% |
| 12M Rtn | 3.9% |
| 3Y Rtn | -12.0% |
| 1M Excs Rtn | -8.5% |
| 3M Excs Rtn | -9.8% |
| 6M Excs Rtn | -24.2% |
| 12M Excs Rtn | -11.7% |
| 3Y Excs Rtn | -69.5% |
Price Behavior
Price Behavior
| Market Price | $2.75 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/06/2016 | |
| Distance from 52W High | -48.6% | |
| 50 Days | 200 Days | |
| DMA Price | $3.41 | $3.61 |
| DMA Trend | up | down |
| Distance from DMA | -19.3% | -23.8% |
| 3M | 1YR | |
| Volatility | 47.4% | 131.6% |
| Downside Capture | 135.01 | 165.54 |
| Upside Capture | -3.46 | 155.98 |
| Correlation (SPY) | 10.3% | 17.4% |
SNOA Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.40 | 0.36 | 0.51 | 0.83 | 1.18 | 1.03 |
| Up Beta | 1.88 | -0.10 | -0.00 | -2.92 | 1.40 | 0.79 |
| Down Beta | -0.36 | -0.64 | 0.09 | 1.17 | 0.24 | 0.92 |
| Up Capture | -57% | 104% | 18% | 160% | 219% | 34% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 6 | 16 | 22 | 44 | 92 | 291 |
| Down Capture | 197% | 103% | 134% | 156% | 130% | 111% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 12 | 23 | 36 | 75 | 148 | 435 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNOA | |
|---|---|---|---|---|
| SNOA | 0.4% | 131.0% | 0.49 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 12.7% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 17.8% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | -6.8% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | 3.9% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 6.6% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 4.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNOA | |
|---|---|---|---|---|
| SNOA | -57.5% | 117.9% | -0.21 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 12.4% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 15.2% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 1.4% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 7.0% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 9.9% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNOA | |
|---|---|---|---|---|
| SNOA | -44.1% | 105.8% | -0.14 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 9.3% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 12.0% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 3.9% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 8.4% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 6.3% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 5.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/10/2026 | 10-Q |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 06/17/2025 | 10-K |
| 12/31/2024 | 02/05/2025 | 10-Q |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 06/17/2024 | 10-K |
| 12/31/2023 | 02/08/2024 | 10-Q |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 06/21/2023 | 10-K |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 07/13/2022 | 10-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.